Doravirine

From WikiProjectMed
Jump to navigation Jump to search
Doravirine
Doravirine structure.svg
Names
Trade namesPifeltro
Other namesMK-1439
  • 3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydro-3-pyridinyl}oxy)benzonitrile
Clinical data
Routes of
use
By mouth[1][2]
External links
AHFS/Drugs.comMonograph
MedlinePlusa618048
Legal
License data
Legal status
Chemical and physical data
FormulaC17H11ClF3N5O3
Molar mass425.75 g·mol−1
3D model (JSmol)
  • Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F
  • InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
  • Key:ZIAOVIPSKUPPQW-UHFFFAOYSA-N

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.

Doravirine was approved for medical use in the United States in August 2018.[5]

References

  1. 1.0 1.1 "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Retrieved 22 September 2020.
  2. Collins S, Horn T. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p. 10. Archived from the original (PDF) on 11 March 2016. Retrieved 6 December 2015.
  3. "Pifeltro 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 1 October 2020.
  4. "Pifeltro EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
  5. "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.

External links

External sites:
Identifiers: